|
|
|
|
|
|
|
|
|
|
|
Estimated
Vaccination Coverage With Selected Vaccines Among Adolescents Aged 13-17*
Years by Age at Interview - National Immunization Survey-Teen, 2010 |
|
| |
|
|
|
|
|
|
|
| Vaccines |
Age at Interview (years) |
|
|
| 13 |
14 |
15 |
16 |
17 |
|
2010 |
| n =3D 3,914 |
n =3D 3,918 |
n =3D 3,942 |
n =3D 3,959 |
n =3D 3,524 |
n =3D 19,257 |
| % (95% CI)† |
% (95% CI) |
% (95% CI) |
% (95% CI) |
% (95% CI) |
% (95% CI) |
| MMR§ ≥ 2 doses |
93.2 (91.9-94.3) |
91.0 (88.9-92.8) |
90.3 (88.4-92.0) |
89.2 (86.8-91.1) |
88.6 (86.3-90.5) |
|
90.5 (89.6-91.3) |
| Hepatitis B ≥ 3 doses |
94.8 (93.7-95.8) |
93.0 (91.0-94.6) |
91.6 (89.7-93.1) |
90.1 (87.7-92.0) |
88.6 (86.5-90.4) |
|
91.6 (90.8-92.4) |
| Varicella |
|
|
|
|
|
|
|
| History
of varicella disease<=
font
class=3D"font12">¶ |
28.5 (25.9-31.2) |
34.5 (31.9-37.3) |
44.3 (41.6-47.1) |
53.8 (50.8-56.9) |
62.6 (59.7-65.4) |
44.7 (43.5-46.0) |
| ≥ 1 dose vaccine if had no
history of disease |
96.4 (95.4-97.2) |
93.2 (91.5-94.6) |
90.0 (87.5-92.0) |
85.0 (80.5-88.5) |
82.2 (78.4-85.4) |
90.5 (89.4-91.5) |
| ≥ 2 doses vaccine if had no
history of disease |
65.8 (62.8-68.8) |
64.3 (61.0-67.5) |
56.4 (52.8-59.9) |
50.7 (45.8-55.6) |
44.2 (39.5-49.0) |
58.1 (56.4-59.8) |
| History
of disease or received ≥ 2 doses varicella vaccination |
75.6 (73.2-77.8) |
76.6 (74.3-78.8) |
75.7 (73.3-78.0) |
77.2 (74.4-79.8) |
79.1 (76.4-81.7) |
76.8 (75.7-77.9) |
| Td or
Tdap** |
|
|
|
| ≥
1 dose Td or Tdap since age 10 years |
78.0 (75.5-80.3) |
82.5 (80.4-84.4) |
82.2 (80.1-84.2) |
82.2 (80.1-84.2) |
81.0 (78.7-83.2) |
81.2 (80.2-82.2) |
| ≥
1 dose Tdap since age 10 years |
73.7 (71.2-76.2) |
77.2 (74.8-79.3) |
72.0 (69.5-74.3) |
65.4 (62.6-68.1) |
54.6 (51.7-57.4) |
68.7 (67.5-69.8) |
| MenACWY†† ≥1 do=
se |
63.8 (61.1-66.5) |
66.6 (64.0-69.1) |
64.0 (61.4-66.5) |
61.8 (58.9-64.5) |
57.1 (54.2-60.0) |
|
62.7 (61.5-63.9) |
| HPV§§ |
|
|
|
| ≥ 1 dose |
38.9 (34.9-43.1) |
48.5 (44.5-52.6) |
51.1 (47.0-55.3) |
51.7 (47.8-55.7) |
53.1 (49.1-57.1) |
48.7 (46.9-50.5) |
| ≥ 3 doses |
23.2 (20.1-26.6) |
30.5 (26.9-34.3) |
31.9 (28.3-35.6) |
36.9 (33.2-40.8) |
37.5 (33.7-41.5) |
32.0 (30.3-33.6) |
| 3 dose series completion¶¶ |
64.1 (55.9-71.5) |
68.2 (61.7-74.0) |
65.6 (59.4-71.3) |
74.3 (69.4-78.7) |
74.6 (68.8-79.6) |
69.6 (66.8-72.2) |
| |
|
|
|
|
|
|
|
|
|
|
|
* Adolesc=
ents in the
2010 NIS-Teen were born during January 1992-February 1998. Vaccination
coverage estimates include only adolescents who had adequately complete
provider-reported immunization records. National estimates do not include
adolescents living in the U.S. Virgin Islands (i.e., St. Croix, St. Thoma=
s,
St. John, and Water Island) (n=3D231). |
|
R=
24;Estimate presented as point estimate (%) ± 95%
confidence interval (CI). |
|
§=
; ≥2 doses of measles, mumps, and rubella vaccine. |
|
¶=
; By
parent/guardian report or provider records. |
|
**
≥1dose of tetanus and diptheria toxoid vaccine (Td), tetanus toxoid,
reduced diptheria toxid, and acellular pertussis (Tdap), or tetanus-unkno=
wn
type vaccine. |
|
R=
24;† X=
05;1
dose of meningococcal conjugate vaccine or meningococcal-unknown type
vaccine. |
|
&sec=
t;§ X=
05;1dose
of human papillomavirus vaccine, either quadrivalent or bivalent. Percent=
ages
reported among females only (n=3D9,220). |
|
&par=
a;¶ Percent of females who received three doses among those w=
ho had
at least one HPV dose and at least 24 weeks between the first dose and the
interview date. |
|
|
|
|
|
|
|
|
|
|
------=_NextPart_01CC60A8.D8E60FF0
Content-Location: file:///C:/C45E1145/tab18_byage_files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"